Edwards Lifesciences has been the subject of discussion due to various factors impacting their market position. There is general optimism over their
growth prospects despite being deemed overbought. Analysts have lauded it as a top pick and a
leading Medical Device Stock. Moreover, there are expectations of a
strong sales growth, projected at 10%, with earnings set to benefit from a growth in
TAVR (Transcatheter Aortic Valve Replacement). An upgrade from
Citigroup reaffirmed their positive outlook, expecting double-digit top line as well as robust growth in the Q1 performance. However, it wasn’t all rosy, with a
class-action lawsuit in the offing involving accusations of securities fraud, and their CEO offloading stock. Mention of a
Class Action investigation could set some investors on edge although, despite this, a planned attendance at the
BofA Securities Health Care Conference and
TD Cowen Annual Health Care Conference is expected to present a front of composure. Their TAVR therapy received
FDA approval for asymptomatic patients, a major progressive step in the medical field.
Regulatory approval for the SAPIEN M3 expanding their product line, and acquisitions of
JenaValve and
Endotronix, potentially boost their standing.
Edwards Lifesciences Corp EW News Analytics from Mon, 15 Jul 2024 07:00:00 GMT to Fri, 30 May 2025 17:39:00 GMT -
Rating 3
- Innovation 2
- Information 8
- Rumor 2
